Should I buy or sell Axonics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares. View AXNX analyst ratings or view top-rated stocks .

What is Axonics' stock price target for 2024?

13 equities research analysts have issued 12-month price targets for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they expect the company's stock price to reach $70.73 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts .

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 at the start of the year. Since then, AXNX shares have increased by 7.6% and is now trading at $66.95. View the best growth stocks for 2024 here .

Are investors shorting Axonics?

Axonics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,440,000 shares, an increase of 17.0% from the March 15th total of 2,940,000 shares. Based on an average trading volume of 1,390,000 shares, the short-interest ratio is currently 2.5 days. View Axonics' Short Interest .

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our AXNX earnings forecast .

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Wednesday, February, 28th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative trailing twelve-month return on equity of 1.00% and a negative net margin of 1.66%. Axonics's quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.01 earnings per share.

What ETFs hold Axonics' stock?

ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , First Trust Merger Arbitrage ETF (MARB) , AltShares Merger Arbitrage ETF (ARB) , ProShares Merger ETF (MRGR) , AltShares Event-Driven ET (EVNT) , IQ Merger Arbitrage ETF (MNA) , Fidelity Digital Health ETF (FDHT) and SPDR S&P Health Care Equipment ETF (XHE) .

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com . Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX) , Oasis Petroleum (OAS) , Pfizer (PFE) , Procter & Gamble (PG) , Thermo Fisher Scientific (TMO) , Cisco Systems (CSCO) , CVS Health (CVS) , AT&T (T) and Abbott Laboratories (ABT) .

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.10%), Diversified Trust Co (0.01%), Fort Pitt Capital Group LLC (0.01%), Los Angeles Capital Management LLC (0.01%) and Inspirion Wealth Advisors LLC (0.01%). Insiders that own company stock include Alfred J Ford Jr , Danny L Dearen , Esteban Lopez , Jane E Kiernan , John Woock , Karen Noblett , Kari Leigh Keese , Raymond W Cohen, Raymond W Cohen and Rinda Sama . View institutional ownership trends .

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free AXNX Stock Alerts

$66.95

-0.10 (-0.15%)

(As of 04:20 PM ET)

Compare

Today's Range: $66.85
▼
$67.13
50-Day Range: $67.05
▼
$69.65
52-Week Range: $47.59
▼
$69.68

Volume: 594,104 shs
Average Volume: 1.29 million shs
Market Capitalization: $3.41 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $70.73

Get Axonics alerts:

Axonics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 5.6% Upside
$70.73 Price Target
Short Interest: Bearish
6.75% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.38
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$4.46 M Sold Last Quarter
Proj. Earnings Growth: 100.00%
From $0.32 to $0.64 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

328th out of 911 stocks

Surgical & Medical Instruments Industry

38th out of 97 stocks

1.2

Analyst's Opinion

Consensus Rating
Axonics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Axonics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.75% of the outstanding shares of Axonics have been sold short.
Short Interest Ratio / Days to Cover
Axonics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Axonics has recently increased by 17.01%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Axonics does not currently pay a dividend.
Dividend Growth
Axonics does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Axonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Axonics is -1.38.

2.7

News and Social Media Coverage

News Sentiment
Axonics has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Axonics this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for AXNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Axonics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,459,798.00 in company stock.
Percentage Held by Insiders
Only 1.85% of the stock of Axonics is held by insiders.
Percentage Held by Institutions
99.48% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Axonics are expected to grow by 100.00% in the coming year, from $0.32 to $0.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Axonics is -514.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Axonics is -514.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Axonics has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXNX Stock News Headlines

April 4, 2024 | reuters.com

FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

March 22, 2024 | businesswire.com

Axonics Stockholders Approve Merger Agreement with Boston Scientific

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 21, 2024 | businesswire.com

Axonics Provides Update on Inter Partes Review Proceedings

March 14, 2024 | businesswire.com

Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

March 1, 2024 | finance.yahoo.com

Axonics Full Year 2023 Earnings: EPS Beats Expectations

February 29, 2024 | marketwatch.com

Axonics Pushes Back Against Patent Dispute Alleged by Medtronic

February 29, 2024 | businesswire.com

Axonics Responds to ITC Action by Medtronic

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 29, 2024 | markets.businessinsider.com

Beyond The Numbers: 7 Analysts Discuss Axonics Stock

February 28, 2024 | finance.yahoo.com

Axonics Inc (AXNX) Reports Robust Revenue Growth and Margin Expansion in Q4 and FY 2023

February 27, 2024 | businesswire.com

AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX

February 3, 2024 | finance.yahoo.com

Insider Sell: Chief Medical Officer Karen Noblett Sells 11,288 Shares of Axonics Inc (AXNX)

January 17, 2024 | finance.yahoo.com

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

January 16, 2024 | realmoney.thestreet.com

Axonics just downgraded at Morgan Stanley, here's why

January 16, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axonics Modulation Technologies (AXNX) and Siemens Healthineers AG (OtherSEMHF)

January 12, 2024 | realmoney.thestreet.com

Axonics just downgraded at Truist, here's why

January 12, 2024 | realmoney.thestreet.com

Axonics just downgraded at CL King, here's why

January 11, 2024 | realmoney.thestreet.com

Axonics just downgraded at Leerink, here's why

January 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Axonics Amid Strategic Acquisition by Boston Scientific

January 9, 2024 | msn.com

Boston Scientific To Acquire Axonics For About $3.7 Bln

January 9, 2024 | msn.com

UPDATE 3-Medical device maker Boston Scientific to buy Axonics for $3.7 billion

January 9, 2024 | markets.businessinsider.com

Analyst Scoreboard: 5 Ratings For Axonics

January 8, 2024 | realmoney.thestreet.com

Axonics just downgraded at RBC Capital, here's why

January 8, 2024 | msn.com

Drugmakers kick off industry conference with two cancer deals

January 8, 2024 | investorplace.com

Why Is Axonics (AXNX) Stock Up 20% Today?

January 8, 2024 | msn.com

Wall Street’s most celebrated bear is not a bull yet. Here’s Mike Wilson’s stock-market playbook for three economic scenarios.

See More Headlines

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:AXNX
CUSIP: N/A
CIK: 1603756
Web: www.axonics.com
Phone: (949) 396-6322
Fax: 949-396-6321
Employees: 797
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $70.73
High Stock Price Target: $75.00
Low Stock Price Target: $63.00
Potential Upside/Downside: +5.8%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 209.00
P/E Growth: N/A
Net Income: $-6,090,000.00
Net Margins: -1.66%
Pretax Margin: -2.39%
Return on Equity: -1.00%
Return on Assets: -0.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.73
Quick Ratio: 8.98

Sales & Book Value

Annual Sales: $366.38 million
Price / Sales: 9.31
Cash Flow: $0.13 per share
Price / Cash Flow: 532.03
Book Value: $12.59 per share
Price / Book: 5.31

Miscellaneous

Outstanding Shares: 51,000,000
Free Float: 50,059,000
Market Cap: $3.41 billion
Optionable: Optionable
Beta: 0.56

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Raymond W. Cohen (Age 65)
CEO & Director
Comp: $1.71M
Mr. Rinda K. Sama (Age 45)
Chief Operating Officer
Comp: $902.83k
Dr. John Woock Ph.D. (Age 41)
Executive VP, Chief Marketing & Strategy Officer
Comp: $902.83k
Mr. Alfred J. Ford Jr. (Age 53)
Chief Commercial Officer
Comp: $902.96k
Ms. Kari Keese
Chief Financial Officer
Mr. Guangqiang Jiang Ph.D. (Age 50)
Chief Technology Officer
Mr. Neil Bhalodkar
Vice President of Investor Relations
Mr. Aaron Pettit
General Counsel & Chief Compliance Officer
Mr. Michael V. Williamson Esq. (Age 52)
J.D., Senior VP, General & IP Counsel
Dr. Karen L. Noblett M.A.S. (Age 61)
M.D., Chief Medical Officer
Comp: $651.4k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings or view top-rated stocks.
What is Axonics' stock price target for 2024?: 13 equities research analysts have issued 12-month price targets for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they expect the company's stock price to reach $70.73 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts.
How have AXNX shares performed in 2024?: Axonics' stock was trading at $62.23 at the start of the year. Since then, AXNX shares have increased by 7.6% and is now trading at $66.95.
View the best growth stocks for 2024 here.
Are investors shorting Axonics?: Axonics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,440,000 shares, an increase of 17.0% from the March 15th total of 2,940,000 shares. Based on an average trading volume of 1,390,000 shares, the short-interest ratio is currently 2.5 days.
View Axonics' Short Interest.
When is Axonics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXNX earnings forecast.
How were Axonics' earnings last quarter?: Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Wednesday, February, 28th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative trailing twelve-month return on equity of 1.00% and a negative net margin of 1.66%. Axonics's quarterly revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.01 earnings per share.

What ETFs hold Axonics' stock?: ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust Merger Arbitrage ETF (MARB), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), AltShares Event-Driven ET (EVNT), IQ Merger Arbitrage ETF (MNA), Fidelity Digital Health ETF (FDHT) and SPDR S&P Health Care Equipment ETF (XHE).
What is Raymond W. Cohen's approval rating as Axonics' CEO?: 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.
What other stocks do shareholders of Axonics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).
When did Axonics IPO?: Axonics (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Axonics' major shareholders?: Axonics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.10%), Diversified Trust Co (0.01%), Fort Pitt Capital Group LLC (0.01%), Los Angeles Capital Management LLC (0.01%) and Inspirion Wealth Advisors LLC (0.01%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends.
How do I buy shares of Axonics?: Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial